Fig. 5From: Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United KingdomDeterministic sensitivity analysis results (incremental cost-effectiveness ratio per quality-adjusted life year). SCT stem cell transplantation, MIDO midostaurin, OS overall survival, HR hazard ratio, CI confidence interval, EFS event-free survivalBack to article page